Figure 5 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
Year: 2025
Type: other
Abstract: A5/158-vc-MMAE impairs sarcoma tumor growth. A, Experimental schematic. 1×106 MG-63-mChLuc2 cells were injected subcutaneously (s.c.) into the flank of NSG mice. On day 14, once tumors reached ∼3 mm in diameter, mice were randomized and began treatment. Mice were treated intravenously (i.v.) with 10 mg/kg of A5/158, Isotype-vc-MMAE, A5/158-vc-MMAE, or vehicle (PBS) twice a week for a total of 4 doses (vehicle, n = 3; A5/158, n = 3; isotype-vc-MMAE, n = 5; A5/158-vc-MMAE, n = 5; red arrows indicate treatment days). B, Bodyweight of treated mice relative to weight on day 0. C, Tumor growth in individual mice measured in tumor diameter and volume. D, Growth rate of tumors (one-way ANOVA, Tukey multiple comparison test). Data shown are mean values ±SEM. E, Final tumor volumes (Kruskal-Wallis, Dunn multiple comparison test) and weights (one-way ANOVA, Tukey multiple comparison test). All are shown as mean values ± SEM. F,Ex vivo images of MG-63 tumors. Scale bar, 10 mm. G, Representative IHC images of MG-63 tumors stained for Endo180. Scale bar, 50 μm. H, Relative Endo180 (MRC2) expression of MG-63 tumors after treatment in comparison with parental MG-63 cells in vitro, analyzed by RT-qPCR and normalized to UBC endogenous control. Data shown are mean values ± SEM.
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4416764646